Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
as in all other end points herein.LTAD as delivered in this study for the treatment of locally advanced prostatecancer is superior to STAD for all end points except survival. A survival advantage for LTAD + RT in the treatment of locally advanced tumors with a Gleason score of 8 to 10 suggests that this should be the standard of treatment for these high-risk patients. (...) Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostatecancer To determine whether adding 2 years of androgen-deprivation therapy (ADT) improved outcome for patients electively treated with ADT before and during radiation therapy (RT).Prostatecancer patients with T2c-T4 prostatecancer with no extra pelvic lymph node involvement and prostate-specific antigen (PSA) less than 150 ng/mL
Screening for prostatecancer in U.S. men: ACPM position statement on preventive practice. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding
Prostatecancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. Biochemical disease recurrence after radical prostatectomy often prompts salvage radiotherapy, but no studies to date have had sufficient numbers of patients or follow-up to determine whether radiotherapy improves survival, and if so, the subgroup of men most likely to benefit.To quantify the relative improvement in prostatecancer-specific survival (...) of salvage radiotherapy vs no therapy after biochemical recurrence following prostatectomy, and to identify subgroups for whom salvage treatment is most beneficial.Retrospective analysis of a cohort of 635 US men undergoing prostatectomy from 1982-2004, followed up through December 28, 2007, who experienced biochemical and/or local recurrence and received no salvage treatment (n = 397), salvage radiotherapy alone (n = 160), or salvage radiotherapy combined with hormonal therapy (n = 78).Prostatecancer
% of patients with advanced prostatecancer, but most tumours relapse within 2 years to an incurable androgen-independent state. The recorded incidence of prostatecancer has substantially increased in the past two decades, probably because of the introduction of screening with prostate-specific antigen, the use of improved biopsy techniques for diagnosis, and increased public awareness. Trends in mortality from the disease are less clearcut. Mortality changes are not of the same magnitude as the changes (...) in incidence, and in some countries mortality has been stable or even decreased. The disparity between reported incidence and mortality rates leads to the probable conclusion that only a small proportion of diagnosed low-risk prostatecancers will progress to life-threatening disease during the lifetime of the patient.
were low quality. Outcomes: mortality and number of men diagnosed with prostatecancer. Secondary outcomes were prostatecancers by stage and grade at diagnosis, metastatic disease, quality of life, costs associated with screening, or harms of screening. MAIN RESULTS Reanalysis using intention to screen showed that groups did not differ for death from prostatecancer in 1 RCT and 1 quasi-RCT, respectively (table). More patients were diagnosed with prostatecancer in the screened group than (...) whether early detection of prostatecancer does more good than harm. In the meantime, some guidelines recommend counselling patients regarding the pros and cons of PSA testing and individualising the screening decision. Men should know that if they choose PSA screening, they substantially increase their lifetime risk of dealing with prostatecancer in exchange for an uncertain reduction in their risk of eventually dying from the disease. Footnotes For correspondence: MrD Ilic, Monash University
Quality of life and satisfaction with outcome among prostate-cancer survivors. We sought to identify determinants of health-related quality of life after primary treatment of prostatecancer and to measure the effects of such determinants on satisfaction with the outcome of treatment in patients and their spouses or partners.We prospectively measured outcomes reported by 1201 patients and 625 spouses or partners at multiple centers before and after radical prostatectomy, brachytherapy (...) satisfaction with the degree of overall treatment outcomes. Changes in quality of life were significantly associated with the degree of outcome satisfaction among patients and their spouses or partners.Each prostate-cancer treatment was associated with a distinct pattern of change in quality-of-life domains related to urinary, sexual, bowel, and hormonal function. These changes influenced satisfaction with treatment outcomes among patients and their spouses or partners.Copyright 2008 Massachusetts Medical
Cumulative Association of Five Genetic Variants with ProstateCancer. Single-nucleotide polymorphisms (SNPs) in five chromosomal regions--three at 8q24 and one each at 17q12 and 17q24.3--have been associated with prostatecancer. Each SNP has only a moderate association, but when SNPs are combined, the association may be stronger.We evaluated 16 SNPs from five chromosomal regions in a Swedish population (2893 subjects with prostatecancer and 1781 control subjects) and assessed the individual (...) and combined association of the SNPs with prostate cancer.Multiple SNPs in each of the five regions were associated with prostatecancer in single SNP analysis. When the most significant SNP from each of the five regions was selected and included in a multivariate analysis, each SNP remained significant after adjustment for other SNPs and family history. Together, the five SNPs and family history were estimated to account for 46% of the cases of prostatecancer in the Swedish men we studied. The five SNPs
Five-alpha-reductase inhibitors reduce the risk of prostatecancer PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They are funded by the New Zealand Guidelines Group. PEARLS provide guidance on whether a treatment is effective or ineffective. PEARLS are prepared as an educational resource and do not replace clinician judgement in the management of individual cases. View PEARLS online (...) at: www.cochraneprimarycare.org Five-alpha-reductase inhibitors reduce the risk of prostatecancer Clinical question How effective are five-alpha-reductase inhibitors (5 ARIs) in preventing prostatecancer? Bottom line 5 ARIs reduce the risk of prostatecancer in men who undergo routine prostatecancer screening* using prostate specific antigen (PSA) and digital rectal examination. However, 71 men aged 55 or older would need to be treated (NNT) with a 5 ARI for up to seven years in order to prevent one case of prostate
treatments for localised prostatecancer Statistics from Altmetric.com T J Wilt Dr T J Wilt, University of Minnesota School of Medicine, Minneapolis, MN, USA; email@example.com QUESTION In men with localised prostatecancer, what is the evidence for effectiveness and harm of various treatments? REVIEW SCOPE Included studies evaluated treatments for localised prostatecancer (tumour stage T1 or T2). Outcomes were all-cause and disease-related mortality, biochemical and clinical progression, and adverse (...) events. REVIEW METHODS Cochrane Library (Issue 3, 2007) and Cochrane Review Group in ProstateDiseases and Urologic Malignancies specialised register (Nov 2007) were searched for randomised controlled trials (RCTs). Other sources were searched for observational studies. 18 RCTs (n = 6482, mean age 63–73 y, mean follow-up 3–23 y), 1 pooled analysis of 3 RCTs (n = 8113, mean age 67 y, median follow-up 5.4 y), … Request Permissions If you wish to reuse any or all of this article please use the link
Diet and dietary supplement intervention trials for the prevention of prostatecancer recurrence: a review of the randomized controlled trial evidence Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
localised prostatecancer. There were limitations in the reporting of the review methods but, overall, the review was well conducted and presented and the authors’ conclusions are likely to be reliable. Authors' objectives To compare the effectiveness and harms of therapies for clinically localised prostatecancer, and to examine the effect of patient, tumour and treatment facility characteristics on the outcomes. This abstract focuses on effectiveness and harms. Searching Randomised controlled trials (...) (RCTs) were sought using the Cochrane Library and the specialised register of the Cochrane ProstaticDiseases and Urologic Cancers Group through September 2007. MEDLINE was searched from 2000 to September 2007 for studies reported in the English language; the search terms were provided. In addition, the results from an existing database containing mainly non-randomised studies, which was used for the Guidelines for the Management of Clinically Localized ProstateCancer: 2007 update (PubMed search
Statin use and the risk of prostatecancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostatecancer: guideline recommendations Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostatecancer: guideline recommendations Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostatecancer: guideline recommendations Morgan S C, Waldron T, Eapen L, Mayhew L A, Winquist E, Lukka H, Genitourinary CancerDisease (...) proceedings of the American Society of Clinical Oncology, American Society for Therapeutic Radiology and Oncology and American Urological Association were searched from 2000 to 2007. Study selection Randomised controlled trials (RCTs) comparing adjuvant external beam radiotherapy to the prostatic bed against observation with therapies held in reserve for salvage were eligible for inclusion in the review. To be included, these trials had to include patients with prostatecancer and either tumour extension
A systematic review of physical activity in prostatecancer survivors: outcomes, prevalence, and determinants Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostatecancer: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
page URL PubMedID Indexing Status Subject indexing assigned by NLM MeSH Antigens, Neoplasm; DNA Methylation; Genetic Predisposition to Disease; Genetic Testing /methodss; Male; Polymorphism, Single Nucleotide /genetics; ProstaticNeoplasms /diagnosis /genetics /immunology; Risk Assessment; Serine Endopeptidases Language Published English Country of organisation United States Address for correspondence BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago (...) Special report: recent developments in prostatecancer genetics and genetic testing Special report: recent developments in prostatecancer genetics and genetic testing Special report: recent developments in prostatecancer genetics and genetic testing BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation BlueCross BlueShield
Androgen suppression and radiation vs radiation alone for prostatecancer: a randomized trial. Comorbidities may increase the negative effects of specific anticancer treatments such as androgen suppression therapy (AST).To compare 6 months of AST and radiation therapy (RT) to RT alone and to assess the interaction between level of comorbidity and all-cause mortality.At academic and community-based medical centers in Massachusetts, between December 1, 1995, and April 15, 2001, 206 men (...) with localized but unfavorable-risk prostatecancer were randomized to receive RT alone or RT and AST combined. All-cause mortality estimates stratified by randomized treatment group and further stratified in a postrandomization analysis by the Adult Comorbidity Evaluation 27 comorbidity score were compared using a log-rank test.Time to all-cause mortality.As of January 15, 2007, with a median follow-up of 7.6 (range, 0.5-11.0) years, 74 deaths have occurred. A significant increase in the risk of all-cause
Benefits and harms of prostate-specific cancer screening: an evidence update for the U.S. Preventive Services Task Force Benefits and harms of prostate-specific cancer screening: an evidence update for the U.S. Preventive Services Task Force Benefits and harms of prostate-specific cancer screening: an evidence update for the U.S. Preventive Services Task Force Lin K, Lipsitz R, Miller T, Janakiraman S Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and harms of prostate-specific cancer screening: an evidence update for the U.S. Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Synthesis No 63. 2008 Authors' objectives To examine new evidence of benefits and harms of screening asymptomatic men for prostatecancer with PSA testing